Table 1.
Summary of experiments on RAS alteration in TBI
| Study (Ref.) | Animal Model | Treatment | Dose and Duration | Result |
|---|---|---|---|---|
| Timaru-Kast, R (Timaru-Kast et al. 2019) | CCI - C57B16N Young, 2 months. Old, 21 months. male mice | Candesartan 10μg/ml | 0.1 mg/kg/ SC/ 30 min after injury | Reduction in brain damage and neurological impairment through microglial response reduction and neutrophil granulocyte infiltration. |
| Janatpour, ZC (Janatpour et al. 2019) | CCI - C57BL/6NCr 8–10-week-old male mice | Ang (1–7) 10.0 mg/mL (micro-osmotic pump); 0.1mg/mL (injections) | 1.0 mg/kg/day 2.5 mg/kg/day |
Ang-(1–7) improved functional recovery and decreases glial activation. |
| Khaksari, M (Khaksari et al. 2018) | Wistar Male rats Diffuse TBI induced by Marmarou method | Candesartan | 0.3 mg/kg IP, 30 min post-TBI | Reduction in brain edema, BBB disruption, oxidant activity, and ICP level using AT1R inhibition. |
| Abdul-Muneer, PM (Abdul-Muneer et al. 2018) | E17 Sprague-Dawley rat embryos Stretch injury | Losartan | (100 μg/mL) 30 min prior to the stretch injury | Losartan downregulated oxidative markers, neuroinflammation and neurodegeneration |
| Villapol, S (Villapol et al. 2015) | CCI - C57BL/6NCr 9-week-old male mice | Candesartan | 0.1, 0.5 or 1 mg/kg IP (after injury) | Neuroprotective. Candesartan is better than telmisartan in chronic condition and low dose of candesartan does not affect blood pressure. |
| C57BL/6J WT control mice AT1R knockout mice | Telmisartan | 1 or 10 mg/kg once per day oral gavage | ||
| PPARγ antagonist (T0070907) | 2 mg/kg (after insult) | |||
| Umschweif, G (Umschweif et al. 2014b) | CHI - Sabra (Weight Drop Injury) 9–10-week-old male mice | AT2 antagonist PD123319 | 10 mg/kg/day for 3 days (after injury) | HA stimulated AT2R and increased neuroprotection and neurogenesis. AT2R inhibition reduced these effects. |
| Timaru-Kast, R (Timaru-Kast et al. 2012) | CCI - C57B16N male mice | Candesartan | low (0.1 mg/kg) med. (0.5 mg/kg) high (1 mg/kg,) SC (30 min after insult) |
AT1R repression declined secondary brain damage and inflammation |
| Umschweif, G (Umschweif et al. 2014a) | CHI - Sabra 9–10-week-old mice | PD 123319 | 10 mg/kg/day | AT2R activation improved neuroprotection and neurogenesis, through different pathways. |
| CGP42112A | 0.1, 1.0, or 10.0 ng/kg/min, 3 days post-CHI | |||
| Villapol, S (Villapol et al. 2012) | CCI - C57BL/6 9-week-old male mice | Candesartan | 1 mg/kg/day | Reduction in neuronal cell death and microglial activation |
| PPARγ antagonist T0070907 | 1.5 mg/kg | |||